Posts Feed
Comments Feed

Archive for the 'Respiratory' Category

Topigen Pharmaceuticals Moves Novel Inhaled Pde Inhibitor, TPI 1100, Into Clinical Development For COPD

Jan 3rd 2009Drug InformationRespiratory

TOPIGEN Pharmaceuticals Inc., a clinical-stage biopharmaceutical company focused in respiratory disorders, today announced that it has received a clinical trial approval (CTA) letter to move TPI 1100, a drug candidate for the treatment of chronic obstructive pulmonary disease (COPD), into clinical development in 2009. TPI 1100 is a novel, inhaled inhibitor against phosphodiesterases (PDEs), PDE 4 and PDE 7. PDEs are a group of enzymes that are validated targets for COPD.

More: continued here

No Comments »

Researchers Identify Gene Linked To Inherited Form Of Fatal Lung Disease

Jan 3rd 2009Drug InformationRespiratory

Researchers at UT Southwestern Medical Center have determined that a mutation in a gene known for its role in defending the lungs against invading pathogens is responsible for some inherited cases of a lethal lung disease affecting older adults. The same mutation may also be associated with lung cancer, the researchers said. This is the third gene that UT Southwestern scientists have linked with idiopathic pulmonary fibrosis, or IPF.

More: continued here

No Comments »

King Of Pop’s Reported Diagnosis Sheds Light On Relatively Unknown Disease

Jan 3rd 2009Drug InformationRespiratory

In light of reports that Michael Jackson is suffering from a rare respiratory condition caused by Alpha 1-Antitrypsin Deficiency, Jeffrey Teckman, M.D., associate professor of pediatrics, biochemistry and molecular biology at Saint Louis University School of Medicine, is available to talk about the diagnosis, causes and treatment of the disease.

More: continued here

No Comments »

« Prev - Next »

1